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Background: Acute lymphoblastic leukemia (ALL) is the most frequently occurring malignant neoplasm in children.
Despite advances in treatment and outcomes for ALL patients, the pathogenesis of the disease remains unclear.
Microarray analysis of samples from 100 Chinese children with ALL revealed the up-regulation of CTCF (CCCTC
binding factor). CTCF is a highly conserved 11-zinc finger protein that is involved in many human cancers; however,
the biological function of CTCF in pediatric ALL is unknown.
Methods: The expression patterns of CTCF were evaluated in matched newly diagnosed (ND), complete remission
(CR), and relapsed (RE) bone marrow samples from 28 patients. The potential oncogenic mechanism of CTCF and
related pathways in leukemogenesis were investigated in leukemia cell lines.
Results: We identified significant up-regulation of CTCF in the ND samples. Importantly, the expression of CTCF
returned to normal levels after CR but rebounded in the RE samples. In the pre-B ALL cell line Nalm-6, siRNA-mediated
silencing of CTCF expression promoted cell apoptosis and reduced cell proliferation; accordingly, over-expression of a
cDNA encoding full-length CTCF protected cells from apoptosis and enhanced cell proliferation. Furthermore,
inhibition or activation of the nuclear factor-kappa B (NF-κB) pathway resulted in marked variations in the levels
of CTCF mRNA and protein in leukemic cells, indicating that CTCF may be involved downstream of the NF-κB
pathway. Moreover, inhibition of the NF-κB pathway increased cell apoptosis, which was partially rescued by
ectopic over-expression of CTCF, suggesting that CTCF may play a significant role in the anti-apoptotic pathway
mediated by NF-κB.
Conclusions: Our results indicate that CTCF serves as both an anti-apoptotic factor and a proliferative factor in
leukemic cells. It potentially contributes to leukemogenesis through the NF-κB pathway in pediatric ALL patients.
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stated.precise risk classification, and personalized chemotherapy
have increased the cure rate of pediatric ALL to approxi-
mately 90% in developed countries [1]. However, a better
understanding of ALL pathogenesis is needed to further
improve the cure rate and quality of life. The advent of
high-throughput, genome-wide gene expression analysis
has provided new insights into leukemogenesis and sug-
gested potential targets for therapy [2,3].
CCCTC-binding factor (CTCF) is a highly conserved
11-zinc finger protein that is involved in multiple regulatory
functions, including transcriptional activation/repression
[4,5], chromatin insulation [6,7], DNA imprinting [8,9],Ltd. This is an Open Access article distributed under the terms of the Creative
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identified and characterized as a transcriptional repressor
of the c-myc gene in chickens, mice, and humans [5,12,13].
Thus, CTCF was considered as a candidate tumor sup-
pressor. However, CTCF also possesses some oncogenic
features. CTCF levels are elevated in breast cancer cell
lines and tumors and are associated with resistance to
apoptosis [14]. CTCF expression in pediatric leukemia
cells has not been investigated.
We previously observed that CTCF mRNA levels are
up-regulated in leukemic cells based on the genome-wide
microarray analysis from 100 Chinese pediatric ALL bone
marrow samples [15,16]. To investigate the biological
function of CTCF in pediatric ALL, we analyzed CTCF
expression in clinical samples at different stages of dis-
ease progression and observed CTCF over-expression
in leukemic cells from both newly diagnosed (ND) and
relapsed (RE) samples. In addition, the expression of CTCF
increased in a similar fashion among the different subtypes
of pediatric ALL samples and cell lines. Increased CTCF
expression in cancer cells could be anti-apoptotic or pro-
mote cell proliferation. Using leukemia cell line Nalm-6,
we demonstrated that knock-down of CTCF increased cell
apoptosis and decreased cell viability; conversely, over-
expression of CTCF rescued cells from apoptosis and
enhanced cell proliferation. We next explored the mechan-
istic basis of CTCF function, which revealed that inhibition
of nuclear factor-kappa B (NF-κB) activity down-regulated
CTCF expression, whereas activation of the NF-κB pathway
restored CTCF expression. Furthermore, inhibition of the
NF-κB pathway increased cell apoptosis in a process that
was partially rescued by ectopic over-expression of CTCF.
To this extent, CTCF may contribute to the pathogenesis
of pediatric ALL by acting as an anti-apoptotic factor via
the NF-κB pathway. These results indicate that CTCF
might serve as a possible therapeutic gene target in future
clinical strategies.
Results
Expression of CTCF in pediatric ALL samples and leukemic
cell lines
Our previous genome-wide microarray analysis of 100
Chinese pediatric ALL cases [15,16] indicated that CTCF
is up-regulated in leukemia cells (Figure 1A). To validate
this finding, we performed qRT-PCR analysis of 10 paired
cDNA samples (n = 20) to determine the transcriptional
levels of CTCF. Each paired sample was obtained from the
same patient at the time of new diagnosis (ND) and
complete remission (CR). CTCF mRNA was elevated in the
ND samples compared with the CR samples (Figure 1B and
Table 1, fold change 2.05, p = 0.000, paired samples t-test),
consistent with the bioinformatics analysis (Figure 1A).
CTCF protein levels were measured by Western blot in
samples from 28 patients (n = 52), including 8 unpairedsamples (n = 8, 4 ND and 4 CR), 16 ND-CR paired sam-
ples (n = 32), and 4 ND-CR-RE matched samples (n = 12)
(Table 2). One bone marrow (BM) sample from a patient
with immune thrombocytopenic purpura (ITP) was selected
as a negative control. CTCF was uniformly expressed at
high levels in the ND samples and reduced to normal
levels upon CR (Figure 2A, 2B, and 2C). Given the outcome
differences among patients with varying cytogenetic ab-
normalities, we assessed paired samples from different
subtypes of ALL, including t(12;21) (TEL-AML1), t(1;19)
(E2A-PBX1), t(9;22) (BCR-ABL) (data not shown), and
other B-ALL (with no translocation). Similar results
were observed among the different subtypes (Figure 2B),
indicating that CTCF expression patterns are independent
of the cytogenetic subtypes.
To investigate the expression features of CTCF in re-
lapsed patients, samples were collected from 4 relapsed
ALL patients. Interestingly, CTCF expression levels
increased again after disease relapse (Figure 2C), sug-
gesting that CTCF might be a sensitive biomarker that
is predictive of relapse.
In addition to the clinical samples, we further determined
the expression features of CTCF in various human lympho-
blastic leukemia cell lines. Two B-lineage ALL (B-ALL) cell
lines Nalm-6 and Reh, and one T-lineage ALL (T-ALL) cell
line Jurkat were evaluated. The Nalm-6 cell line contains
no fusion gene, whereas the Reh cell line carries the TEL-
AML1 fusion gene. As shown in Figure 2D, no differences
of CTCF mRNA levels were observed among three types of
leukemia cells (p = 0.831, one-way ANOVA). Accordingly,
CTCF protein in these cells displayed similar expression
patterns, consistent with the change in clinical samples.
In view of the fact that approximately 85% of pediatric
ALL cases are B-ALL and nearly 80% cases are with no
chromosomal and molecular genetic abnormalities [1],
Nalm-6 is selected to further explore the potential onco-
genic mechanism of CTCF in leukemogenesis.
The effect of CTCF knock-down on apoptosis and
proliferation in leukemic cells
The high expression of the zinc finger protein CTCF in
leukemic cells prompted us to investigate whether CTCF
could affect apoptosis or proliferation in lymphoblastic
cells. To further determine the effect of altered CTCF
activity on cell apoptosis and proliferation, two CTCF
shRNA-expressing plasmids (sh-CTCF-1 and sh-CTCF-2)
were constructed. The shRNA plasmid specific for fire-
fly luciferase (sh-luc) was used as a control. The RNA
interference efficiency of the shRNAs was evaluated by
Western blot and parallel semi-quantitative analysis
in Nalm-6 cells. Our data revealed that sh-CTCF-2
was more effective at knock-down than sh-CTCF-1
(Figure 3A); hence, sh-CTCF-2 was selected for the
subsequent assays.
Figure 1 CTCF levels are dramatically up-regulated in pediatric ALL cases. (A) A heat map of CTCF mRNA levels (blue box). The fold change
in expression compared with the control is indicated by the color intensity, with red representing up-regulation. Refer to the additional file 4 of
reference [16] for more details. HD, hyperdiploid>50 chromosomes. (B) CTCF mRNA levels were measured by qRT-PCR in paired cDNA samples
from 10 ALL patients (n = 20). Each paired sample refers to two samples from the same patient at the time of ND and CR. CTCF mRNA levels were
increased in the ND samples compared with the CR samples (fold change 2.05, p = 0.000, paired samples t-test). Each assay was repeated three
times. ND, newly diagnosed. CR, complete remission.
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Table 1 Clinical features of the 10 paired pediatric ALL cases and qRT-PCR data





mRNA levels of CTCF
ND CR p value
1 M 2 Common B cell - - Remission 0.328 0.118
Paired Samples T test:
ND-CR, p = 0.000
2 M 5 Common B cell t(12;21) TEL-AML1 Remission 0.313 0.098
3 M 7 Common B cell t(1;19) E2A-PBX1 Remission 0.275 0.142
4 F 3 Common B cell t(12;21) TEL-AML1 Remission 0.249 0.146
5 M 2 Common B cell t(12;21) TEL-AML1 Remission 0.314 0.124
6 F 3 Common B cell t(12;21) TEL-AML1 Remission 0.371 0.220
7 M 4 Common B cell t(12;21) TEL-AML1 Remission 0.327 0.127
8 F 3 Common B cell t(12;21) TEL-AML1 Remission 0.251 0.157
9 M 3 Pre-B cell t(12;21) TEL-AML1 Remission 0.195 0.112
10 F 8 Pro-B cell - - Remission 0.341 0.205
ND: newly diagnosis; CR: complete remission.

















1 F 10 5.2 Common B cell 89.5 - - Remission
2 M 5 10.5 T cell 98 - - Remission
3 M 2 24 Common B cell 99.5 - - Remission
4 F 7 4.9 Common B cell 99.5 - - Remission
5 M 6 79 Common B cell 93 - - Remission
6 M 6 4.9 Common B cell 96 - - Remission
7 F 10 6.6 Common B cell 96 - - Remission
8 M 5 17.4 Common B cell 90.5 t(12;21) TEL-AML1 Remission
Paired samples
9 F 3 101 Common B cell 99 t(12;21) TEL-AML1 Remission
10 M 4 84 Common B cell 95 t(12;21) TEL-AML1 Remission
11 F 8 113 Pro-B cell 97.5 - - Remission
12 M 2 17 Common B cell 89.5 - - Remission
13 M 7 2.4 Common B cell 99 - - Remission
14 F 2 6.8 Common B cell 98 - HOX11 Remission
15 M 6 18.4 Common B cell 92.5 t(9;22) BCR-ABL Remission
16 F 2 6 Common B cell 94.5 t(12;21) TEL-AML1 Remission
17 M 5 68.2 Common B cell 96 t(1;19) E2A-PBX1 Remission
18 M 7 6.9 Common B cell 95 t(1;19) E2A-PBX1 Remission
19 F 8 113 Common B cell 99 t(1;19) E2A-PBX1 Remission
20 F 3 39.3 Common B cell 96 t(12;21) TEL-AML1 Remission
21 M 3 65 Pre-B cell 97.5 t(12;21) TEL-AML1 Remission
22 F 3 14 Common B cell 92.5 t(12;21) TEL-AML1 Remission
23 M 5 5.4 Common B cell 88.5 t(12;21) TEL-AML1 Remission
24 M 2 10 Common B cell 87.5 t(12;21) TEL-AML1 Remission
Relapsed samples
25 M 0.58 (7 months) 120 Common B cell 91.5 MLL Dead
26 M 15 24.5 Common B cell 96 - - Dead
27 M 10 10.3 Common B cell 97.5 - - Dead
28 M 9 14 Common B cell 98 - - Dead
WBC, white blood cell; PB, peripheral blood; BM, bone marrow.
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Figure 2 CTCF expression patterns in pediatric ALL samples and leukemic cell lines. (A) Western blot analysis of unpaired samples
from 8 patients (n = 8, 4 ND and 4 CR). CTCF was over-expressed in the ND samples and displayed reduced expression after CR. A sample
from one pediatric patient with immune thrombocytopenic purpura (ITP) was used as a negative control, and GAPDH was used as a loading
control. (B) Western blot analysis of paired samples taken from 16 pediatric ALL patients (n = 32). The results from 3 patients are shown,
including 1 patient with a t(1;19) (E2A-PBX1) translocation, 1 with a t(12;21) (TEL-AML1) translocation, and 1 without any translocations. CTCF
was over-expressed in the ND samples and displayed reduced expression after CR. (C) The expression of CTCF rebounded after relapse and
maintained normal levels in the CR phase. A total of four relapsed cases were assessed, and the results from two cases are presented. (D) The
mRNA and protein levels of CTCF in various lymphoblastic leukemia cell types were evaluated by real-time PCR and Western blot. The relative
mRNA expression levels were analyzed and presented as mean ± SD from triple replications (p = 0.831). Nalm-6 is a pre-B ALL cell line with no
fusion gene. Reh is a pre-B ALL cell line with the TEL-AML1 fusion gene. Jurkat is T lymphocyte cell line. GAPDH was measured as the
loading control.
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of the shRNA plasmids. Because all the plasmids carried a
GFP tag, we detected cell apoptosis in GFP-positive cells
sorted by flow cytometry. As expected, CTCF knock-down
by sh-CTCF-2 resulted in a 2-fold increase in early cell
apoptosis and an approximately 15-fold increase in late
cell apoptosis (Figure 3B and 3C). Consistent with these
findings, CTCF knock-down by sh-CTCF-2 decreased
the expression of inactive procaspase-3, and triggered the
activation of cleaved-caspase-3, indicating that inhibition
of CTCF leads to activation of the apoptotic pathway in
leukemic cells (Figure 3D).
We next sought to determine whether CTCF knock-
down has deleterious effects on cell viability. Leukemic
cells treated with CTCF-specific shRNAs consistently
showed at least a 40% decrease in cell viability (Figure 3E
and 3F, p = 0.018, paired samples t-test). These data support
the notion that CTCF activity is involved in both leukemic
cell death and proliferation.The effect of CTCF over-expression on apoptosis and
proliferation in leukemic cells
To determine whether CTCF over-expression could
rescue leukemic cells from the induction of apoptosis,
the over-expression plasmid pEGFP-N2-CTCF was con-
structed from an in-frame fusion of CTCF and an
enhanced-GFP tag (Figure 4A). In this experiment, pEGFP-
N2-CTCF and the empty plasmid pEGFP-N2 were transi-
ently transfected into the leukemic cell line. Expression
levels from the transfected plasmids (pEGFP-N2-CTCF
and pEGFP-N2) were assessed by Western blot (Figure 4B).
As shown in Figures 4C and 4D, ectopic over-expression of
CTCF rescued approximately 50% of early apoptotic cells
from apoptosis. Additionally, the effect of over-expressed
CTCF on cell apoptosis was further determined by ana-
lyzing caspase-3 activities. However, over-expression of
CTCF in transfected Nalm-6 cells resulted in a counter
effect against caspase-3 activation, and no cleaved caspase-
3 was detected (Figure 4B).
Figure 3 The effect of CTCF knock-down on apoptosis and proliferation in leukemic cells. (A) sh-CTCF-1 and sh-CTCF-2 are shRNA plasmids
specific for CTCF. sh-luc (targeting firefly luciferase) is the shRNA plasmid specific for firefly luciferase and was used as a negative control. CTCF
expression levels were semi-quantified by analysis of the Western blot with Gel-Pro Analyzer software. The sh-CTCF-2 plasmid showed better
knock-down efficiency than the sh-CTCF-1 plasmid. (B) Knock-down of CTCF resulted in increased early cell apoptosis [Annexin V (+)/PI (−)] and
late cell apoptosis [Annexin V (+)/PI (+)]. The percentages of cells in early and late apoptosis are indicated in the figure, respectively. sh-luc was
used as a control. (C) The percentage of cell apoptosis (both early and late apoptosis) in each group is shown in the diagram as mean ± SD from
three independent experiments (p = 0.001). (D) Effect of knocking down CTCF mRNA on caspase-3 activation in Nalm-6 cells. The expression levels
of procaspase-3, cleaved caspase-3 and transfected plasmids were determined using Western blot. (E) Knock-down clones were seeded in a
96-well plate at 1 × 104 cells per well, with three replicates per clone. Viable cells were counted using the CCK-8 assay for 5 days. (F) The percentage
of cell viability normalized to nonspecific sh-luc is presented as mean ± SD from three independent experiments.
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of CTCF over-expression on leukemic cell proliferation.
An approximately 30% increase in cell viability was
observed (Figure 4E and 4F, p = 0.047, paired samples
t-test). However, the changes in cell apoptosis and pro-
liferation were not as prominent as those observed in
the knock-down experiments, primarily due to increased
basal levels of CTCF in leukemic cells. These resultsdemonstrate that CTCF serves as both an anti-apoptotic
and proliferative factor in leukemic cells.
The effect of NF-κB pathway inhibition on CTCF expression
in leukemic cells
The transcription factor NF-κB is involved in many key
cellular processes and has emerged as a major regulator
of programmed cell death (PCD) via apoptosis or necrosis
Figure 4 The effect of CTCF over-expression on apoptosis and proliferation in leukemic cells. (A) A schematic outline of the pEGFP-N2-CTCF
expression vector. The full-length CTCF gene was cloned into the pEGFP-N2 vector. (B) Effect of over-expressing CTCF on caspase-3 activation in
Nalm-6 cells. The expression levels of procaspase-3, cleaved caspase-3 and the transfected plasmids were assessed by Western blot. (C) Over-expression of
CTCF resulted in decreased early cell apoptosis [Annexin V (+)/PI (−)] and late cell apoptosis [Annexin V (+)/PI (+)]. The percentages of cells in early and
late apoptosis are indicated in the figure, respectively. pEGFP-N2 vector was used as a control. (D) The percentage of cell apoptosis (both early and late
apoptosis) in each group is indicated in the diagram as mean ± SD from three independent experiments (p = 0.012). (E) Clones over-expressing CTCF
were seeded in a 96-well plate at 1 × 104 cells per well, with 3 replicates per clone. Viable cells were counted using the CCK-8 assay for 5 days. (F) The
percentage of cell viability normalized to the empty vector pEGFP-N2 is shown in the diagram.
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important role in tumorigenesis. NF-κB possesses im-
portant regulatory functions for both normal and malig-
nant hematopoiesis and is constitutively activated in
pediatric ALL samples [18]. Therefore, we investigated
whether the NF-κB pathway is involved in the anti-
apoptotic or proliferative effects of CTCF in leukemic
cells. To test this hypothesis, the effect of NF-κB on CTCF
expression was examined via inhibition of NF-κB activity
with ammonium pyrrolidinedithiocarbamate (PDTC),
a NF-κB specific inhibitor. The activation of the NF-κB
pathway was evaluated by Western blot using a specific
antibody against nuclear p65 (Figure 5A). After inhibition
of NF-κB activity, CTCFmRNA levels decreased (Figure 5B,fold change 2.49, p = 0.000). CTCF protein levels were
down-regulated accordingly, consistent with the change
in mRNA levels (Figure 5C, fold change 1.89). These
data indicate that CTCF is likely involved downstream
of the NF-κB pathway in leukemic cells.
The effect of NF-κB pathway activation on CTCF expression
in leukemic cells
To further elucidate the regulatory role of CTCF in the
NF-κB pathway, we treated Nalm-6 cells with different
concentrations (5 or 10 μg/ml) of lipopolysaccharide (LPS),
a potent activator of the NF-κB pathway [19]. The nuclear
translocation of NF-κB p65 was enhanced with increasing
LPS concentrations, indicating that the NF-κB pathway was
Figure 5 Expression of CTCF in leukemic cells before and after
treatment with an inhibitor of NF-κB activity. (A) Nalm-6 cells
were treated with the NF-κB inhibitor PDTC or DMSO (negative
control) for 20 h. NF-κB pathway activity was detected by Western
blot using a nuclear p65-specific antibody. Histone H3 and α-tubulin
were used as the loading controls for nuclear and cytoplasmic
proteins, respectively. (B) CTCF mRNA levels in cell lysates were
measured by real-time PCR. The relative changes in the expression levels
were analyzed and presented as mean ± SD from triple replications (fold
change 2.49, p= 0.000). (C) Cell lysates were probed with an anti-CTCF
antibody, and the expression levels of CTCF were semi-quantified by
analyzing the Western blot with Gel-Pro Analyzer software (fold change
1.89). GAPDH was used as a loading control.
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Figure 6B, NF-κB pathway activation with 5 or 10 μg/ml
LPS resulted in a 1.33-fold (p = 0.027, paired samples t-test)
and 1.66-fold (p = 0.025, paired samples t-test) increase inCTCF mRNA, respectively. Correspondingly, the protein
level increased in a dose-dependent manner by 1.53-fold
and 1.72-fold, respectively (Figure 6C). These data demon-
strate that CTCF is regulated by NF-κB factors and may
play a role downstream of the NF-κB pathway.
The effect of CTCF on cell apoptosis and proliferation in
PDTC-induced leukemic cells
As previously shown, CTCF knock-down significantly
increased Annexin V staining of Nalm-6 cells and de-
creased cell viability. To further determine whether CTCF
was involved in the apoptotic or proliferative pathway me-
diated by NF-κB, we over-expressed CTCF in combination
with treatment with PDTC or DMSO. After a 20-h pre-
treatment of Nalm-6 cells with PDTC or DMSO, the
over-expressing plasmids were transiently transfected;
cellular apoptosis and viability were detected 48 h after
transfection. Interestingly, the results demonstrated that
ectopically over-expressed CTCF partially rescued the
Annexin V stained cells, particularly the late apoptotic
cells induced by the NF-κB-inhibitor PDTC (Figure 7A
and 7B). By contrast, CTCF over-expression did not rescue
the PDTC-induced proliferative inhibition of leukemic cells
(Figure 7C, p = 0.070, paired samples t-test). Caspase-3
assay and the expression levels of the transfected plasmids
were also assessed by Western blot (Figure 7D). These
data imply that CTCF plays an important role in the anti-
apoptotic pathway mediated by NF-κB factors.
Discussion
CTCF functions as an epigenetic regulator and transcrip-
tion factor that controls gene expression and cell fate. In B
cell lymphomas, increased expression of CTCF is associated
with down-regulation of c-myc, resulting in cell growth
arrest and apoptosis [20]. Accumulation of CTCF in hu-
man K562 myeloid cells leads to growth inhibition and
promotion of differentiation into the erythroid lineage
[21]. Ectopic expression of CTCF in many cell types in-
hibits cell clonogenicity by causing growth retardation
without apoptosis [22]. Sufficient evidence proves that
CTCF could be a tumor suppressor gene. However,
other studies have provided evidence contradicting a
pro-apoptotic or anti-proliferative role of CTCF. CTCF
knock-down triggers apoptosis in breast cancer cells,
whereas over-expression of CTCF partially protects cells
from Bax-induced apoptosis [14]; CTCF mRNA knock-
down promotes stress-induced apoptosis in human corneal
epithelial cells [23]. These contradictory results led us to
investigate the biological function of CTCF in pediatric
ALL.
Our previous genome-wide microarray analysis of sam-
ples from 100 children with ALL revealed that CTCF
mRNA was over-expressed. The present study revealed that
the mRNA and protein levels of CTCF are up-regulated in
Figure 6 Expression of CTCF in leukemic cells before and after treatment with an activator of NF-κB activity. (A) Nalm-6 cells were treated
with different doses (5 or 10 μg/ml) of the NF-κB activity activator LPS for 12 h. NF-κB pathway activity was detected by Western blot using a nuclear
p65-specific antibody. Histone H3 and α-tubulin were used as the loading controls for nuclear and cytoplasmic proteins, respectively. (B) CTCF mRNA
levels in cell lysates were measured by real-time PCR. The relative changes in the expression levels after treatment with 5 and 10 μg/ml LPS were
analyzed and presented as mean ± SD from triple replications (fold change 1.33, p= 0.027; fold change 1.66, p= 0.025, respectively). (C) Cell lysates were
probed with an anti-CTCF antibody, and the expression levels of CTCF were semi-quantified by analyzing the Western blot with Gel-Pro Analyzer software.
The fold changes in expression after treatment with 5 and 10 μg/ml LPS were 1.53 and 1.72, respectively. GAPDH was used as a loading control.
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following chemotherapy, suggesting that CTCF may serve
as a promising indicator of disease progression and treat-
ment response.Although intensive chemotherapy combined with potent
supportive care has improved the survival conditions
of pediatric ALL patients, the overall cure rate has not
significantly increased in recent years. Approximately
Figure 7 Over-expression of CTCF rescues the cell apoptosis and proliferation induced by an NF-κB activity inhibitor. (A) Nalm-6 cells
were treated with the NF-κB inhibitor PDTC or DMSO for 20 h before transient transfection with the over-expressing plasmids. Cellular apoptosis
was assessed by flow cytometry analysis of Annexin V-APC/PI staining at 48 h after transfection. The percentages of cells in early apoptosis
[Annexin V (+)/PI (−)] and late apoptosis [Annexin V (+)/PI (+)] are indicated in the figure, respectively. (B) The percentage of cell apoptosis (both
early and late apoptosis) in each group is indicated in the diagram as mean ± SD from three independent experiments (**p = 0.000). (C) Clones
over-expressing CTCF were seeded in a 96-well plate at 1 × 104 cells per well, with three replicates per clone. Viable cells were counted using the
CCK-8 assay for 5 days. (D) Caspase-3 activation and the expression levels of the transfected plasmids were measured by Western blot.
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failure. Notably, this study revealed CTCF expression
signatures associated with disease relapse. A total of 4
relapsed ALL patients were enrolled in this study to
observe the changes in CTCF expression during different
disease phases. We observed that CTCF expression in-
creased again upon disease relapse but remained at
normal levels in the CR samples. This finding indicates that
CTCF levels increased as the malignant clones expanded
and were detectable for a brief time before disease recur-
rence. Additional clinical samples should be studied to
confirm these findings.
Leukemia is recognized as a progressive, malignant
disease caused by distorted differentiation, apoptosis,
and proliferation of hematopoietic cells at different stages.
The levels of CTCF were elevated rather than decreased
in pediatric ALL samples, which is not characteristic of a
tumor suppressor and inspired us to further examine this
finding. We hypothesized that over-expression of CTCF
may protect leukemic cells from apoptotic cell death orpromote cancer cell proliferation. As expected, reduced
CTCF levels caused apoptotic cell death and proliferative
inhibition in leukemic cell lines. These results indicate a
possible link between CTCF expression and sensitivity to
apoptosis and proliferation. Specifically, increased CTCF
levels may be necessary to protect against apoptotic
stimuli and promote leukemic cell viability. These findings
may be relevant to the potential use of CTCF as a thera-
peutic target in pediatric ALL because reducing CTCF
levels could result in apoptotic cell death and growth
inhibition of cancer cells without affecting normal blood
cells, although further studies are needed.
CTCF over-expression has been reported to induce
apoptosis and growth retardation in various cell types
[20-22]. Undoubtedly, our results introduce a controversial
role for the tumor suppressor CTCF in apoptosis and
proliferation. Cell type, cellular environment, genetic
background, and other variables play important roles in
the ultimate function of CTCF. The combination of these
factors often has conflicting effects, making it difficult to
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For example, WT-1 [24-27] may behave as either an
anti-apoptotic or pro-apoptotic factor in different cellular
contexts. Previous study reported such a controversial role
of CTCF in breast cancer cells [14] and human corneal
epithelial cells [23], which strongly support our findings.
In this study, we suggest a similar dual role for CTCF in
pre-B ALL cells.
Explanation of this complex behavior will require a
better understanding of regulatory networks. Increased
CTCF levels in leukemic cells may be involved in the
development of apoptotic resistance and increased cell
proliferation. NF-κB is a multi-component pathway that
controls hundreds of genes involved in diverse cellular
processes, including cell proliferation, cellular growth,
and apoptosis. Dysregulation of the pathway leads to many
human diseases, such as cancer [28]. Here, we demon-
strated that changes in NF-κB activation by either a NF-κB-
inhibitor or a NF-κB-activator affected CTCF mRNA and
protein expression in leukemic cells, suggesting that CTCF
is involved downstream of the NF-κB pathway.
To further explore the functional role of CTCF in the
NF-κB pathway, we determined that ectopic over-expression
of CTCF effectively rescues Nalm-6 cells from apoptotic
death rather than proliferative inhibition, indicating that
CTCF is primarily involved in the anti-apoptotic pathway
mediated by NF-κB in leukemic cells. However, the ability
of CTCF to rescue cells from apoptotic death induced by
an NF-κB-inhibitor cannot be explained solely by this
pathway. The regulation of cell apoptosis and proliferation
by CTCF also involves other pathways, such as the extra-
cellular signal-regulated kinase (Erk) and Akt signaling
pathways [29]. Further studies are needed to clarify the
direct and indirect effects of CTCF on this regulation. In
addition, several unanswered questions must be addressed,
including which NF-κB subtype interacts with CTCF in
leukemic cells and which network regulates CTCF in-
volvement in the NF-κB signaling pathway.Conclusions
In this paper, which is the first to link the zinc finger
protein CTCF with pediatric ALL, the following conclu-
sions are made. 1) CTCF expression patterns could
serve as a sensitive indicator of CR and RE in ALL. 2)
Our results support the hypothesis that increased levels
of the CTCF protein can protect leukemic cells against
apoptosis and promote cell proliferation, indicating that
CTCF is a promising target for anti-leukemic therapy.
3) CTCF is involved downstream of the NF-κB signaling
pathway and plays an important role in the anti-apoptotic
pathway mediated by NF-κB. In future studies, additional
samples and regulatory network research will be investi-
gated to elucidate the role of CTCF in pediatric ALL.Materials and methods
Patient information
A total of 28 children (7 months to 15 years, median age of
5 years) diagnosed with ALL and treated in the Hematology
Oncology Center of Beijing Children’s Hospital between
December 2002 and April 2009 were enrolled in this study.
Informed consent was obtained from the parents or legal
guardians of the patients. A single sample was obtained
from a child with immune thrombocytopenic purpura
(ITP) as a negative control. The study design followed
the Helsinki guidelines and was approved by the Beijing
Children’s Hospital Ethics Committee prior to initiating
the study.
All patients were diagnosed with ALL using a combin-
ation of morphology, immunology, cytogenetics, and mo-
lecular biology (MICM). The cytogenetic ALL subtypes
were experimentally identified by G-banding karyotype
and multiplex nested reverse transcription-polymerase
chain reaction (RT-PCR). A total of 29 fusion genes were
assessed by RT-PCR, including TEL-AML1, BCR-ABL,
E2A-PBX1,MLL-AF4, and SIL-TAL1.
Paired bone marrow (BM) samples from 16 pediatric
patients (n = 32) were collected at the time the patient was
characterized as newly diagnosed (ND) or in complete
remission (CR). From these samples, 10 (n = 20) were
randomly selected for quantitative real-time PCR (qRT-
PCR) analysis (Table 1). In addition, 8 unpaired BM sam-
ples (n = 8) from 4 ND and 4 CR patients were collected.
Matched BM samples were also collected from 4 relapsed
patients at the time of ND, CR, and relapse (RE) (n = 12).
The clinical features of these patients are described in
detail in Table 2.
Cell samples, RNA isolation, and qRT-PCR
BM samples were collected in ethylenediaminetetraacetic
acid (EDTA) tubes. Mononuclear cells were isolated by
Ficoll gradient centrifugation (MD Pacific, Tianjin, China,
density: 1.077 g/ml) and cryo-preserved in a −80°C freezer
for subsequent experiments. Total RNA from the BM
samples and cell lines was extracted using Trizol reagent
(Invitrogen, Paisley, UK) and the mirVana™ Protein and
RNA Isolation System (Ambion, USA), respectively, ac-
cording to the manufacturers’ instructions. cDNA was
synthesized using random hexamers and Moloney murine
leukemia virus reverse transcriptase (Promega, Madison,
USA). For BM samples, qRT-PCR was performed with the
GenomeLab GeXP Genetic Analysis System (Beckman
Coulter, CEQ8000, USA) using the GenomeLab™ GeXP
Start Kit (Beckman Coulter, USA). The GAPDH gene was
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CATGACGAACAT-3′. The qRT-PCR reaction was per-
formed with a starting temperature of 95°C for 10 min,
followed by 35 cycles of 30 s at 94°C, 30 s at 55°C, and
1 min at 72°C. Each assay was repeated three times to
ensure reproducibility and reliability. For cell lines, real-
time PCR was done as described previously [16]. The
threshold cycle (Ct) values for both CTCF and GAPDH on
each PCR array were used to calculate the fold-changes
in mRNA expression. The relative expression level was
normalized to the GAPDH by the method of 2-ΔΔCt.
Plasmid construction and preparation
The full-length cDNA encoding human CTCF (727 amino
acids, NP_006556.1) was cloned into the pEGFP-N2 vector
(EcoRI/ApaI digestion), which carries an enhanced-GFP
tag; the resulting construct was named pEGFP-N2-CTCF.
For the RNA interference (RNAi) experiment, the U6
promoter-driven shRNA expression vector pNeoU6 + 1
and the shRNA plasmid specific for firefly luciferase
(sh-luc) were prepared by our lab facility [30]. Both
plasmids contain a GFP tag. The two target sites in the
CTCF mRNA coding regions were sh-CTCF-1 (658–677,
ATGTAGATGTGTCTGTCTAC) and sh-CTCF-2 (953–
971, TACTCGTCCTCACAAGTGC). These targeted se-
quences were verified as unique sequences in the human
genomic and transcriptional sequence database (NCBI).
The plasmids were purified using a Plasmid Mini Kit
(Omega, Bio-tek, USA) in accordance with the manufac-
turer’s instructions.
Generation of antibodies and Western blot
The anti-CTCF polyclonal antibody was generated by
injecting the pET28a-CTCF antigen into a rabbit. The
pET28a-CTCF antigen was constructed by inserting
the N-terminal region of CTCF (amino acids 1–280) into
the pET28a expression vector. The antiserum had good
specificity and could be used to detect human CTCF by
Western blot. The anti-GAPDH antibody was produced
by the animal center of our institution [16].
Samples containing 20 μg of total protein were separated
on 8%~ 12% SDS-PAGE gels according to the different
molecular weight and then transferred onto nitrocellulose
membranes (Whatman, Germany) in transfer buffer
(25 mM Tris-base, 40 mM glycine, and 20% methanol)
using a Mini Trans-Blot Cell (BIO-RAD) at 400 mA
for 2 h. The membranes were blocked by incubation in
5% nonfat milk in TBS-T (20 mM Tris, 137 mM NaCl,
and 0.1% Tween 20) for 1 h at room temperature. Proteins
were detected using specific rabbit polyclonal anti-CTCF
(1:2,000) or rabbit polyclonal anti-GAPDH (1:5,000) anti-
bodies. After washing with TBS-T, the membranes were in-
cubated with goat anti-rabbit immunoglobulin G secondary
antibodies (1:5,000, Pierce, USA) in TBS-T containing 5%nonfat milk for 45 min at room temperature. The proteins
were visualized using an enhanced chemiluminescence kit
(Amersham, USA).
Cell culture and drug treatment
Nalm-6 is a pre-B ALL cell line with no fusion gene,
while Reh is a pre-B ALL cell line with the TEL-AML1
fusion gene. Jurkat is a T-lineage ALL cell line. Cells
were cultured in a modified HyQ RPMI-1640 medium
(Hyclone, USA) supplemented with 10% fetal bovine
serum (FBS, PAA, USA) in a 5% CO2 humidified atmos-
phere at 37°C. In the NF-κB-inhibited drug experiments,
the cells were treated with ammonium pyrrolidinedithio-
carbamate (PDTC, 100 μM/ml) [31] or dimethyl sulfoxide
(DMSO) for 20 h. In the NF-κB-activated drug experi-
ments, the cells were treated with various concentrations
of lipopolysaccharides (LPS, 5 or 10 μg/ml) [19] for 12 h.
The cells were harvested and washed twice with PBS. The
cells were incubated on ice for 30 min in 1× cell lysis
buffer [20 mM Tris, 50 mM NaCl, 2 mM Na3VO4,
10 mM NaF, 1 mM EDTA, 0.1% Triton X-100, and Pro-
teinase Inhibitor Cocktail (Roche)] and then sonicated.
Following centrifugation at 4°C for 30 min, the superna-
tants were frozen at −80°C or used immediately.
Nuclear protein extraction and determination of NF-κB
activation
Nuclear proteins (including NF-κB p65) were isolated
and analyzed by Western blot. The cells were washed
twice with ice-cold PBS and suspended in NE buffer A
[10 mM Hepes-NaOH (pH 7.9), 1.5 mM MgCl2, 10 mM
KCl, proteinase inhibitor, 1 mM DTT, and 1 mM PMSF].
Intact nuclei were released from the cells by several washes
with NE buffer B [NE Buffer A supplemented with 0.3%
NP-40]. Nuclear membranes were damaged by adding NE
buffer C [12.5% glycerol, 1mMTris-HCl (pH 6.5), 0.1 mM
EDTA], followed by three cycles of sonication. A mouse
monoclonal anti-p65 antibody (1:2,000, Santa Cruz, USA)
was used to analyze the translocation of NF-κB to nuclei
by standard Western blot analysis as described above. A
rabbit polyclonal anti-histone H3 CT pan antibody (1:5,000,
Upstate, USA) and a mouse monoclonal anti-α-tubulin
antibody (1:10,000, Sigma, USA) were used as loading
controls for nuclear and cytoplasmic proteins, respectively.
Transient transfection, cellular apoptosis, and proliferation
assays
In the knock-down and over-expression experiments, the
shRNA and over-expressing plasmids were transiently
transfected into Nalm-6 cells (2 × 106 seeding density)
using the Amaxa Cell Line Nucleofector Kit T and the
Nucleofector Device (Lonza, Swiss) according to the
manufacturer’s instructions. The cells were incubated
for 72 h in 2 ml of antibiotic-free media containing
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Western blot. A total of 1 × 104 cells per well were seeded
in a 96-well plate after transfection, with triplicate seedings
per clone. Viable cells were counted using the Cell Count-
ing Kit-8 (CCK-8, Dojindo, Japan) assay for 5 days accord-
ing to the manufacturer’s instructions. All values were
normalized to the non-treated cells (sh-luc plasmid and
pEFG-N2 vector). For the drug treatment experiments,
PDTC or DMSO was added to the Nalm-6 cells to inhibit
NF-κB activation 20 h prior to the transfection of pEGFP-
N2-CTCF or pEGFP-N2. The cells were harvested for
apoptosis analysis and Western blot 48 h after transfec-
tion. Cell viability was assessed by CCK-8 analysis as
described above.
For the apoptotic assays, GFP-positive cells were sorted
and collected by flow cytometry (BD, FACSAria II, USA)
to measure the silencing efficiency. The percentages of
Annexin V-APC/PI stained (BD, USA) positive and nega-
tive cells were analyzed with FlowJo software. Besides,
caspase-3 activity in cells was further determined by
Western blot using specific mouse monoclonal antibody
against caspase-3 (Beyotime Institute of Biotechnology,
Nanjing, China), which contains specificities for detecting
both procaspase-3 (1:500) and cleaved caspase-3 (1:250).
Semi-quantitative analysis
Western blots were subjected to semi-quantitative analysis
using Gel-Pro Analyzer 4.0 software. The relative expres-
sion level of CTCF was normalized to the integrated optical
density (IOD) of CTCF compared with GAPDH (loading
control).
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